Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBIT (2019 - 2025)

Historic EBIT for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $65.5 million.

  • Harmony Biosciences Holdings' EBIT rose 612.06% to $65.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.6 million, marking a year-over-year increase of 2871.96%. This contributed to the annual value of $190.8 million for FY2024, which is 62.7% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its EBIT stood at $65.5 million for Q3 2025, which was up 612.06% from $48.2 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' EBIT ranged from a high of $65.5 million in Q3 2025 and a low of $11.9 million during Q3 2022
  • In the last 5 years, Harmony Biosciences Holdings' EBIT had a median value of $40.4 million in 2023 and averaged $40.0 million.
  • Its EBIT has fluctuated over the past 5 years, first soared by 44204.69% in 2023, then plummeted by 5446.68% in 2024.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' EBIT stood at $28.6 million in 2021, then soared by 66.3% to $47.6 million in 2022, then decreased by 15.58% to $40.2 million in 2023, then soared by 38.64% to $55.7 million in 2024, then grew by 17.51% to $65.5 million in 2025.
  • Its last three reported values are $65.5 million in Q3 2025, $48.2 million for Q2 2025, and $56.2 million during Q1 2025.